Metabolomic Analysis Using Liquid Chromatography/Mass Spectrometry for Gastric Cancer.
Metabolomics is a post-genomics research field for analysis of low molecular weight compounds in biological samples and has shown great potentials for elucidating complex mechanisms associated with diseases. However, metabolomics studies on gastric cancer (GC), which is the second leading cause of cancer death worldwide, remain scarce, and the molecular mechanisms to metabolomics phenotypes are also still not fully understood. This study reports that the metabolic pathways can be exploited as biomarkers for diagnosis and treatment of GC progression as a case study. Importantly, the urinary metabolites and metabolic patterns were analyzed by high-throughput liquid chromatography mass spectrometry (LC-MS) metabolomics strategy coupled with chemometric evaluation. Sixteen metabolites (nine upregulated and seven downregulated) were differentially expressed and may thus serve as potential urinary biomarkers for human GC. These metabolites were mainly involved in multiple metabolic pathways, including citrate cycle (malic acid, succinic acid, 2-oxoglutarate, citric acid), cyanoamino acid metabolism (glycine, alanine), primary bile acid biosynthesis (glycine, taurine, glycocholic acid), arginine and proline metabolism (urea, L-proline), and fatty acid metabolism (hexadecanoic acid), among others. Network analysis validated close association between these identified metabolites and altered metabolic pathways in a variety of biological processes. These results suggest that urine metabolic profiles have great potential in detecting GC and may aid in understanding its underlying mechanisms. It provides insight into disease pathophysiology and can serve as the basis for developing disease biomarkers and therapeutic interventions for GC diseases.